Results 151 to 160 of about 2,368 (193)

Formulary Drug Reviews: Nirsevimab

Hospital Pharmacy, 2023
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Terri L. Levien, Danial E. Baker
openaire   +2 more sources

Nirsevimab: First Approval

Drugs, 2022
Nirsevimab (Beyfortus®), a long-acting intramuscular recombinant neutralising human IgG1ĸ monoclonal antibody to the prefusion conformation of the respiratory syncytial virus (RSV) F protein that has been modified with a triple amino acid substitution in the Fc region to extend the serum half-life, is being jointly developed by AstraZeneca and Sanofi ...
openaire   +2 more sources

AN INTRODUCTION TO NIRSEVIMAB

Preventive Paediatrics
Respiratory syncytial virus (RSV) is a dominating respiratory infection worldwide.  It is responsible for infecting millions of children worldwide each winter through highly contagious droplets and secretions. Over 2.1 million of these children require some form of medical attention during illness.
Ivana Kalanovic Dylag, Andrew Dylag
openaire   +1 more source

Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-world global database

Journal of Infection
: Objective: The preventive effect of nirsevimab, a long-acting monoclonal antibody, on infants with respiratory syncytial virus (RSV) infection beyond six months has rarely been evaluated.
Shinya Tsuzuki, Taito Kitano
exaly   +2 more sources

Nirsevimab and Hospitalization for RSV Bronchiolitis

New England Journal of Medicine
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody against RSV that has an extended half-life. Its postlicensure real-world effectiveness against RSV-associated bronchiolitis is unclear.We conducted a prospective, multicenter, matched ...
Assad, Zein, Romain, Anne-Sophie, Aupiais, Camille, Shum, Mickaël, Schrimpf, Cécile, Lorrot, Mathie, Corvol, Harriet, Prevost, Blandine, Ferrandiz, Charlène, Giolito, Anna, Valtuille, Zaba, Bendavid, Matthieu, Cohen, Jérémie, Toubiana, Julie, de Pontual, Loïc, Delande, Camille, Levy, Michael, See, Perrine, Cohen, Robert, Levy, Corinne, Angoulvant, François, Lenglart, Léa, Gits-Muselli, Maud, Biran, Valérie, Diallo, Kadiatou, Alemede, Oluwafunmilola, El Hebil, Mohamed, Durrmeyer, Xavier, Labouret, Géraldine, Casanovas, Natacha, Hallak, Benjamin, Maréchal, Olympe, Jung, Camille, Bréhin, Camille, Ouldali, Naïm   +34 more
openaire   +2 more sources

Parent Perspectives on Nirsevimab for Their Newborn

Pediatrics
BACKGROUND In 2023, nirsevimab, a monoclonal antibody against respiratory syncytial virus (RSV), was approved in the United States to be given to infants to prevent bronchiolitis, a leading cause of pediatric hospitalizations.
Sarah, Hinderstein, Elena, Aragona, Jaspreet, Loyal   +2 more
openaire   +2 more sources

Race-Based Guidance and Nirsevimab

JAMA Pediatrics
This Viewpoint discusses the current Advisory Committee on Immunization Practices and American Academy of Pediatrics race-based guidelines on the administration of nirsevimab and suggested race-conscious revision of the current guidance.
Joshua T B, Williams, Florence, Wu
openaire   +2 more sources

Nirsevimab: A Review

Pediatric Allergy, Immunology, and Pulmonology
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in people of all ages and is the leading cause of hospitalization among infants in the United States. The year 2023 was exciting for RSV prevention. The Food and Drug Administration (FDA) approved 3 new tools for preventing severe lower respiratory tract RSV ...
openaire   +2 more sources

Balanced on the Biggest Wave: Nirsevimab for Newborns

Neonatal Network
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete
Christopher, McPherson, Christine R, Lockowitz, Jason G, Newland   +2 more
openaire   +2 more sources

Nirsevimab Administration During the Birth Hospitalization

Hospital Pediatrics
BACKGROUND Respiratory syncytial virus (RSV) is the leading cause of newborn hospitalization. In July 2023, nirsevimab, a monoclonal antibody to protect infants against RSV and reduce severe illness, was approved. Nirsevimab is the newest birth hospitalization immunization.
Shayda, Daneshvari, Philip, Lee, Sheri L, Nemerofsky   +2 more
openaire   +2 more sources